A 56-year-old woman has nausea due to chemotherapy for breast cancer. Droperidol is effective in reducing nausea because it blocks wof
First, I need to recall the mechanism of action of droperidol. Droperidol is an antipsychotic medication, but it's also used for its antiemetic properties. I remember that it has dopamine receptor blocking activity. Dopamine receptors are involved in the vomiting reflex, so blocking them would prevent nausea and vomiting.
Now, the vomiting center in the brainstem is influenced by various receptors. The main ones involved in chemotherapy-induced nausea are dopamine D2 receptors. Chemotherapy agents can stimulate the chemoreceptor trigger zone (CTZ), which is rich in D2 receptors. By blocking these receptors, droperidol inhibits the vomiting reflex.
Looking at the options, the correct answer should be D2 receptors. The other options might be other receptors like serotonin (5-HT3), histamine (H1), or muscarinic (M1) receptors. But since the question is about droperidol, the primary mechanism is D2 blockade.
Let me verify if there's any other receptor involved. Droperidol also has some anti-histamine and anti-cholinergic properties, but its main antiemetic effect is through D2. So, even though it might block other receptors to some extent, the primary and most significant is D2.
For the incorrect options: 5-HT3 antagonists are another class used for chemotherapy-induced nausea, like ondansetron. H1 and M1 blockers are more for motion sickness or other types of nausea. So the distractors would be these other receptors.
The clinical pearl here is that dopamine antagonists are first-line for CINV, and droperidol specifically targets D2 receptors. Also, it's important to note that droperidol is not commonly used now due to risks like QT prolongation, but it's still a classic medication for this indication.
**Core Concept**
Droperidol is a dopamine receptor antagonist primarily used for its antiemetic effects. It acts by blocking dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) of the brainstem, which is a key pathway in chemotherapy-induced nausea and vomiting (CINV).
**Why the Correct Answer is Right**
Droperidol’s antiemetic activity stems from its ability to antagonize dopamine D2 receptors in the CTZ. Chemotherapy agents stimulate the CTZ, triggering the vomiting reflex via dopamine release. By blocking D2 receptors, droperidol prevents this stimulation, inhibiting the vomiting center in the medulla oblongata. This mechanism is distinct from 5-HT3 antagonists (e.g., ondansetron), which are also used for CINV but target a different receptor. D2 blockade is the primary mechanism for droperidol’s efficacy in this context.
**Why Each Wrong Option is Incorrect**
**Option A:** If this option refers to 5-HT3 receptors, it is incorrect. 5-HT3 antagonists are a separate class of antiemetics, not the primary mechanism of droperidol.
**Option B:** If this option refers to H1 histamine receptors,